Managing the care of people with diabetes is costly and time intensive,
especially for our nation’s primary care providers who shoulder 80% of
that responsibility. Virtual care programs have the potential to fill
critical gaps and meet increasing demands, but can they produce real
This press release features multimedia. View the full release here:
Glytec and Onduo, who formed a business alliance last year, are partnering with HIMSS on a webinar that explores the keys to augmenting traditional brick-and-mortar care with virtual care for people with diabetes. (Graphic: Business Wire)
who formed a business alliance last year, are partnering with HIMSS on a
webinar that explores the keys to augmenting traditional
brick-and-mortar care with virtual care for people with diabetes. The
two companies will reflect on their real-world experiences and expertise
in this rapidly-evolving space.
You may register for the webinar here.
Virtual Diabetes Care: Unlocking
the Keys to Real Results
May 30, 2019
2-3 pm Central
12-1 pm Pacific
Dr. Ronald Dixon, Head
of Clinical Affairs and President of the Physician Group at Onduo
Andrew Rhinehart, Chief Medical Officer at Glytec
• The model for a
successful virtual care program, including the combination of connected
diabetes technologies and care management services.
• Why insulin
therapy optimization is a mission critical element.
• How A1C and
time in range play a central role in value-based reimbursement.
Evidence surrounding the clinical and economic impacts of A1C and
• The benefits to patients and providers when
traditional care is augmented by virtual care, and how both groups are
responding to virtual care.
• Real-world data showing sustained A1C
reductions of 2.7% points and higher.
Founded in 2006, Glytec is the pioneer of
digital therapeutics, improving the lives of people with diabetes by
making insulin a more effective and accessible option for millions
unable to achieve their treatment goals. The company’s patented
eGlycemic Management System® is the only FDA-cleared
software-as-a-medical-device (SaMD) platform to enable the mass
personalization of insulin across the continuum of care: inpatient,
outpatient and virtual settings alike. Glytec offers several
comprehensive programs combining evidence-based decision support
technologies with expert professional services proven to aid providers
in achieving best practices and standardization while reducing
hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost.
The company has offices in Waltham, Massachusetts and Greenville, South
Carolina. For more information visit www.glytecsystems.com.